Cargando…

The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control

Detalles Bibliográficos
Autores principales:	Knudsen, Erik S., Zacksenhaus, Eldad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089558/ https://www.ncbi.nlm.nih.gov/pubmed/30123416 http://dx.doi.org/10.18632/oncotarget.25797

Ejemplares similares

Timing is everything: Rb’s choice in islet-cell fate
por: Cai, Erica P, et al.
Publicado: (2014)

Methylation data of mouse Rb-deficient pineoblastoma
por: Chung, Philip E.D., et al.
Publicado: (2020)

Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift
por: Ciavarra, Giovanni, et al.
Publicado: (2010)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Critical Role of the Rb Family in Myoblast Survival and Fusion
por: Ciavarra, Giovanni, et al.
Publicado: (2011)

Progression to Metastasis of Solid Cancer
por: Zacksenhaus, Eldad, et al.
Publicado: (2021)

CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
por: Shrestha, Mariusz, et al.
Publicado: (2023)

Loss of Rb launches cell cycle
por: Tuma, Rabiya
Publicado: (2003)

A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling
por: Wang, Dong-Yu, et al.
Publicado: (2019)

RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs
por: Robinson, Tyler J. W., et al.
Publicado: (2013)

Targeting RB1 Loss in Cancers
por: Linn, Paing, et al.
Publicado: (2021)

Targeting HER2(+) breast cancer: the TBK1/IKKε axis
por: Jiang, Zhe, et al.
Publicado: (2014)

Relevance of pRB Loss in Human Malignancies
por: Mandigo, Amy C., et al.
Publicado: (2022)

A Tumor initiating cell-enriched prognostic signature for HER2(+):ERα(−) breast cancer; rationale, new features, controversies and future directions
por: Liu, Jeff C., et al.
Publicado: (2013)

RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
por: Han, Wanting, et al.
Publicado: (2022)

Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer
por: Wang, Sharon, et al.
Publicado: (2016)

RB pockets the cell cycle
por: Lai, Eric C.
Publicado: (2003)

Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells
por: Ju, YoungJun, et al.
Publicado: (2021)

Molecular stratification within triple-negative breast cancer subtypes
por: Wang, Dong-Yu, et al.
Publicado: (2019)

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2(+):ERα(-) breast cancer
por: Liu, Jeffrey C., et al.
Publicado: (2017)

Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma
por: Jiang, Zhe, et al.
Publicado: (2002)

Future Challenges in Nocturia: Relevance to Voiding Clock?
por: Lee, Tack
Publicado: (2011)

ANT1 and the SASP: Beyond the Bioenergetic Void
por: Rangarajan, Sunad
Publicado: (2023)

RB in DNA repair
por: Huang, Paul H., et al.
Publicado: (2015)

RB in glutamine metabolism
por: Clem, Brian
Publicado: (2014)

Differential role of RB in response to UV and IR damage
por: Bosco, Emily E., et al.
Publicado: (2005)

Elevated PI3K signaling drives multiple Breast Cancer subtypes
por: Adams, Jessica R., et al.
Publicado: (2011)

Study on the Voiding Detection System Using Wearable Device
por: Hwang, Young Seon
Publicado: (2018)

Current Challenges of Geriatric Voiding Dysfunction in South Korea
por: Cho, Sung Tae
Publicado: (2016)

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
por: Brough, Rachel, et al.
Publicado: (2018)

Targeting the RB-E2F pathway in breast cancer
por: Johnson, Jackie, et al.
Publicado: (2016)

Targeting the Vulnerabilities of Oncogene Activation
por: Huang, Christina, et al.
Publicado: (2023)

Establishing a Belgian Nutrition Society (BNS): Filling the Void
por: Cani, Patrice, et al.
Publicado: (2009)

Pan-cancer molecular analysis of the RB tumor suppressor pathway
por: Knudsen, Erik S., et al.
Publicado: (2020)

RB depletion is required for the continuous growth of tumors initiated by loss of RB
por: Doan, Alex, et al.
Publicado: (2021)

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
por: Knudsen, Erik S., et al.
Publicado: (2022)

Lipid Metabolism as a Targetable Metabolic Vulnerability in Colorectal Cancer
por: Zaytseva, Yekaterina
Publicado: (2021)

Multiple molecular interactions redundantly contribute to RB-mediated cell cycle control
por: Thwaites, Michael J., et al.
Publicado: (2017)

The Void
por: Close, Frank
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_9n3693b8seknbiae6or8250gh3